Piper Jaffray Cuts Price Target on Eli Lilly & Co. (LLY) Following Announced Discontinuation of Evacetrapib

Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration

October 13, 2015 7:00 AM EDT

LOS ANGELES and INDIANAPOLIS, Oct. 13, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and ImaginAb Inc. are pleased to announce a preclinical research collaboration to study potential novel T-cell-based immuno-oncology therapies.

Per the agreement, ImaginAb will conduct preclinical research using its immune imaging agent, IAB22M2C (a clinical anti-human CD8 probe), to detect T-cell trafficking, redirection and infiltration in response to Lilly oncology molecules. ImaginAb maintains full rights to its proprietary imaging agents used as part of the research project. Financial terms were not disclosed.

There is compelling... More

Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease

October 12, 2015 8:01 AM EDT

INDIANAPOLIS, Oct. 12, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and the ACCELERATE study's academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational medicine evacetrapib, due to insufficient efficacy. Lilly will discontinue development of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease and will now conclude other studies in the program.

The independent data monitoring committee based its recommendation on data from periodic data reviews, which suggested there was a low probability the study would... More

Lilly and Innovent Biologics Expand Their Strategic Alliance to Include Immuno-Oncology Bispecific Antibodies in China and Globally

October 11, 2015 10:00 PM EDT

INDIANAPOLIS and SHANGHAI, Oct. 11, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Innovent Biologics, Inc. (Innovent) today announced an expansion of their drug development collaboration, already one of the largest in China between a multi-national and domestic biopharmaceutical company.

Below are details of the expanded agreement:

The companies will collaborate to support the development and potential commercialization of up to three anti-PD-1 based bispecific antibodies for cancer treatments over the next decade, both inside and outside of China. Under the previous agreement, Lilly will exercise its... More

Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions

October 9, 2015 4:00 PM EDT

INDIANAPOLIS, Oct. 9, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia's intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. Intranasal glucagon, which is currently in Phase III clinical trial testing, could be the first needle-free rescue treatment for severe hypoglycemia.

Intranasal glucagon uses a proprietary glucagon nasal powder formulation that is delivered in an emergency situation using a single-use, ready-to-use device. The caregiver presses a small... More

Eli Lilly and Company Expands New York City Research and Development Site

October 9, 2015 7:00 AM EDT

INDIANAPOLIS, Oct. 9, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to add 30,000 square feet and approximately 50 new jobs to its research and development presence at the Alexandria Center for Life Science in New York, New York.

Upon completion in 2016, this space will include a translational immuno-oncology hub and a Lilly "portal," which will provide local academic scientists with opportunities for collaborative access to cutting-edge drug discovery capabilities, including chemistry and lead optimization expertise.

"Going forward, immuno-oncology research will focus on new ways to harness the immune... More